Navigation Links
FDA: New Warnings Required on Use of Gadolinium-Based Contrast Agents
Date:9/9/2010

rtain agents among patients at highest risk for nephrogenic systemic fibrosis," said Rafel (Dwaine) Rieves, M.D., director of the Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research.

To further enhance the safe use of the imaging agents, the FDA recommends that health care professionals:

  • Estimate kidney function through laboratory testing for patients at risk for chronically reduced kidney function
  • Avoid use of GBCAs in patients suspected or known to have impaired drug elimination unless the imaging is essential and not available without contrast
  • Monitor for signs and symptoms of NSF if a GBCA is administered to a patient with acute kidney injury or chronic, severe kidney disease
  • Administer a GBCA only once during an imaging session

Magnevist is marketed by Bayer Healthcare, Omniscan by GE Healthcare, and Optimark by Covidien.

For more information:

Gadolinium Safety Announcement

http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm

Questions and Answers on Gadolinium-Based Contrast Agents

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142889.htm

Media Inquiries: Karen Riley, 301-796-4674; karen.riley@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
2. PTCB Certification Required for Pharmacy Technician Employment by Department of Veterans Affairs
3. Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website
4. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
5. Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging
6. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
7. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
8. Federal Agents Seize FastSize Extenders and FastSize EQM™ Erectile Quality Monitors
9. VisEn Announces New ProSense® 750 FAST and Neutrophil Elastase™ 680 FAST Fluorescence Molecular Imaging Agents at European Molecular Imaging Meeting 2010
10. Epix Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Epix Imaging Agents to June 22, 2010
11. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Now available for sale, The ... support that prevents ankle sprains by cushioning the ankle ... fits securely around the outside of any shoe type ... comfort while still offering protection against sprains. With customers ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... Pharmaceuticals, Inc. (Nasdaq: AMPE ), a biopharmaceutical ... (Zertane™ completed two phase III studies, Ampion™-completed ... these drugs and engaged in further drug development, today ... the US Patent Office of an additional patent that ...
... March 19, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... an emerging leader in the development, assembly, marketing ... products, today announced its financial results for the ... (Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO ) ...
Cached Medicine Technology:Ampio Strengthens Patent Protection for Lead Drug Ampion™ 2Ampio Strengthens Patent Protection for Lead Drug Ampion™ 3Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 2Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 3Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 4Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 5Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 6Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 7Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 8Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 9Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 10Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 11Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 12Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 13Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 14Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 15
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to ... Pharmacy Services at North Carolina State’s College of Veterinary ... Beal Award for Distinguished Volunteer Service—the organization’s highest award. ... contributions of volunteer experts to direct its work to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... Houston, TX (PRWEB) January 22, 2015 The ... Pro Bodybuilder Ben Pakulski to increase lean muscle by up ... This has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting ... shows that it is a step-by-step, scientific diet formula that ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... , , BOSTON, July 29 ... 2009, its annual summer scientific meeting, in Boston, July 29 - ... Anticipated attendance is more than 4,000. World-renowned leaders in the field ... diagnosis and medical, surgical and cosmetic treatment of skin, hair and ...
... , , MORRISTOWN, N.J., July ... leader in generic and specialty branded pharmaceuticals, today reported net income ... as detailed in the reconciliation table below, adjusted net income for ... an increase of $15.8 million or 29 percent. Adjusted EBITDA for ...
... , , , ... ) today announced that second quarter 2009 net income was $693.5 million, or ... income in the second quarter of 2008 was $750.5 million, or $1.44 per ... , "We are pleased with our earnings per share results for ...
... ... world , ... July 28, 2009 -- Announcing the first HelpDesk for GCP in the world. A much ... means to bring modern science and technology to diseased patients., , ,With the increase in ...
... Generation Rescue ... the autism community in order to help children and educate parents and medical professionals. , ... Los Angeles, CA (Vocus) July 29, 2009 -- ... meet the needs of the autism community in order to help children and educate parents and ...
... ... Provider Maximizes Performance with the TEDS Talent Management Suite. , ... Johnson City, TN (PRWEB) July 29, 2009 ... today the rollout of the TEDS® Talent Management Suite. TEDS is now live for ...
Cached Medicine News:Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 5Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 6Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 7Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 8Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 9Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 10Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 11Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 12Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 13Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 14Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 15Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 16Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 17Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 18Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 19Health News:WellPoint Reports Second Quarter 2009 Results 2Health News:WellPoint Reports Second Quarter 2009 Results 3Health News:WellPoint Reports Second Quarter 2009 Results 4Health News:WellPoint Reports Second Quarter 2009 Results 5Health News:WellPoint Reports Second Quarter 2009 Results 6Health News:WellPoint Reports Second Quarter 2009 Results 7Health News:WellPoint Reports Second Quarter 2009 Results 8Health News:WellPoint Reports Second Quarter 2009 Results 9Health News:WellPoint Reports Second Quarter 2009 Results 10Health News:WellPoint Reports Second Quarter 2009 Results 11Health News:WellPoint Reports Second Quarter 2009 Results 12Health News:WellPoint Reports Second Quarter 2009 Results 13Health News:WellPoint Reports Second Quarter 2009 Results 14Health News:WellPoint Reports Second Quarter 2009 Results 15Health News:WellPoint Reports Second Quarter 2009 Results 16Health News:WellPoint Reports Second Quarter 2009 Results 17Health News:WellPoint Reports Second Quarter 2009 Results 18
... Increased volume for use with 4, 8, ... bottom permits withdrawal of nearly all of the ... excess solution. Made of natural virgin polystyrene containing ... by irradiation. Dimensions: 78 mm W x 152 ...
Volume: 5 ml; Volume Graduation: 1/10 ml...
Precise, safe, and fatigue-free series pipetting using graduated pip...
An adhesive-backed hanger, designed for use where space is limited (fume hoods, sterile hoods, etc.). Sticks to any smooth, dry surface without damage. Resistant to chemicals and UV light....
Medicine Products: